Last reviewed · How we verify
Rivastigmine 5 and 10 cm^2 patch — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rivastigmine 5 and 10 cm^2 patch (Rivastigmine 5 and 10 cm^2 patch) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rivastigmine 5 and 10 cm^2 patch TARGET | Rivastigmine 5 and 10 cm^2 patch | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rivastigmine 5 and 10 cm^2 patch CI watch — RSS
- Rivastigmine 5 and 10 cm^2 patch CI watch — Atom
- Rivastigmine 5 and 10 cm^2 patch CI watch — JSON
- Rivastigmine 5 and 10 cm^2 patch alone — RSS
Cite this brief
Drug Landscape (2026). Rivastigmine 5 and 10 cm^2 patch — Competitive Intelligence Brief. https://druglandscape.com/ci/rivastigmine-5-and-10-cm-2-patch. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab